Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092298 · ClinicalTrials.gov registry record · Phase 2
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
A Phase 2 study of Gastrointestinal Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02092298 is a Phase 2 study of Gastrointestinal Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 233-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02092298, a Phase 2 study of Gastrointestinal Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer. The safety of this treatment will also be studied.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Mitomycin C
- DRUG Sodium Thiosulfate
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-05-08 |
| Est. Completion | 2020-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092298
The ClinicalTrials.gov registry entry for NCT02092298 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02092298 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02092298 about?
NCT02092298 is a clinical study titled "Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer". The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer. The safety of this treatment will also be studied.
What is the current status of trial NCT02092298?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2014-05-08. Estimated completion is 2020-05-12.
What conditions does trial NCT02092298 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT02092298?
The interventions under investigation include: Cisplatin (DRUG), Mitomycin C (DRUG), Sodium Thiosulfate (DRUG).
Who is sponsoring clinical trial NCT02092298?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02092298 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
RECRUITING · Phase 2
-
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
RECRUITING · Phase 2
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.